Increasing Prevalence of Chronic Diseases to Augment the Hospital Pharmaceuticals Market Growth
Hospital pharmaceuticals consist of medicines purchased for
hospitals, healthcare centers to be administered to patients during
hospitalization. Hospital pharmaceuticals include therapeutic and critical care
drugs applied in infections, neurology, urology, cardiology, hematology,
dermatology, respiratory system, musculoskeletal system, sensory organs, alimentary
tract and metabolism, and other. The primary responsibility of hospital
pharmacy is procurement, storage and selling of medications.
Market Dynamics:
Increasing incidence or prevalence of chronic diseases
across the world, especially in the North America, is expected to propel the
growth of the hospital pharmaceuticals market. For instance, chronic diseases
such as diabetes, cancer, and heart disease, are the leading causes of death
and disability in the United States, according to the Centers for Disease
Control and Prevention (CDC). They are also leading drivers of the nation's
$3.8 trillion in annual health care costs.
Moreover, the emergence of COVID-19 (SARS-CoV-2) is expected
to augment the growth of the hospital
pharmaceuticals market. For instance, in February 2021, Facing the
challenge of a fast-paced and complex rollout of COVID-19 vaccines,
Pennsylvania Hospital deployed radio frequency identification (RFID) technology
to track the status of every vial that is removed from an ultra-freezer, then
transported to the vaccination clinic, and sometimes returned to refrigeration,
all while ensuring no vial expires before reaching a patient's arm.
Increasing demand for hospital pharmaceuticals and increasing
spending on pharmaceuticals is also expected to fuel the growth of the hospital
pharmaceuticals market. However,
Competitive Analysis:
Major players operating in the hospital pharmaceuticals market
are Eli Lilly and Company, Merck & Co., Sanofi S.A., F. Hoffmann-La Roche
Ltd, Johnson & Johnson, GlaxoSmithKline Plc., AstraZeneca Plc., Pfizer,
Inc., Novartis AG, and Bayer AG.
Major players in the market are adopting various strategies,
such as partnership, collaboration, product launch, etc., to enhance their
market presence. For instance, in February 2021, Recce Pharma Ltd. formalized
an agreement with Fiona Stanley Hospital for a Phase 1/2 clinical trial to
assess the potential of RECCE 327’s new spray-on, broad-spectrum antibiotic for
the treatment of topical burn wound infections.
In February 2021, Algernon Pharmaceuticals provided an
update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19
Ifenprodil study.
In February 2021, Valeo Pharma and Ingenew Pharma announced
that HespercoTM capsules, approved by Health Canada for immune support, will be
at the core of the Montreal Heart Institute's clinical trial, "The
Hesperidin Coronavirus Study".
Comments
Post a Comment